Could taking a break from CLL drug improve outcomes for frail patients?
NCT ID NCT04963946
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study looks at whether older, frail patients with untreated chronic lymphocytic leukemia (CLL) can safely stop taking the targeted drug acalabrutinib after 18 months and then restart it only if their disease comes back. The goal is to reduce long-term side effects and lower the chance of drug resistance. About 160 patients aged 70 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARGENTEUIL - Centre hospitalier Victor Dupouy
Argenteuil, France
-
BOBIGNY - Hôpital Avicenne
Bobigny, France
-
Bordeaux Pessac
Pessac, 33604, France
-
CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique
Perpignan, 66000, France
-
CERGY-PONTOISE - Centre Hospitalier René Dubos
Pontoise, France
-
CHR ORLEANS - Hématologie
Orléans, 44100, France
-
CHU Estaing - Hématologie Clinique Adulte
Clermont-Ferrand, 63000, France
-
CHU Grenoble - Hématologie
Grenoble, 388043, France
-
CHU Nancy Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU Pontchaillou - Hématologie Clinique BMT-HC
Rennes, 35033, France
-
Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Regional Metz Thionville
Metz, 57085, France
-
Centre Hospitalier du Mans
Le Mans, 72000, France
-
Centre Léon Bérard - Hématologie
Lyon, 69373, France
-
Ch Avignon
Avignon, 84000, France
-
Ch Cote Basque
Bayonne, 64109, France
-
Chu Angers
Angers, 49933, France
-
Chu Reims
Reims, 51092, France
-
Corbeil-Essonnes -
Corbeil-Essonnes, France
-
Hopital E.Muller
Mulhouse, 68100, France
-
Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent
Paris, 75651, France
-
Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, 37044, France
-
Hôpital Privé Sévigné
Cesson-Sévigné, 35510, France
-
Hôpital Saint Vincent de Paul
Lille, 59000, France
-
Hôpital Saint-Eloi - Hématologie Clinique
Montpellier, 34295, France
-
Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
Poitiers, 86021, France
-
IUCT ONCOPOLE - Hématologie
Toulouse, 31059, France
-
Institut Paoli-Calmettes - Hématologie Clinique
Marseille, 13273, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42271, France
-
VERSAILLES - Hôpital André Mignot
Versailles, France
-
Vannes - Chba
Vannes, France
Conditions
Explore the condition pages connected to this study.